<DOC>
	<DOCNO>NCT02571192</DOCNO>
	<brief_summary>The purpose study determine SHP626 absorb excrete body healthy male .</brief_summary>
	<brief_title>A Study Investigate How Study Drug SHP626 Eliminated From Body After One Dose</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>1 . Age 18 50 year , inclusive , time consent . 2 . Must consider healthy . Healthy status define absence evidence active chronic disease follow detailed medical surgical history , complete physical examination include vital sign , 12lead ECG , hematology , thyroid panel ( include T3 , T4 TSH Screening ) , blood chemistry , coagulation urinalysis 3 . Must body mass index 18.030.0kg/mÂ² inclusive body weight &gt; 50 kg ( 110 lb ) . 4 . Ability swallow investigational product . 5 . A minimum 1 bowel movement per day . 1 . History hematological , hepatic , respiratory , cardiovascular , renal , neurological psychiatric disease , gallbladder removal , gastric bypass surgery , ileal resection , small intestinal resection , current recurrent disease could affect action , absorption , disposition investigational product , clinical laboratory assessment . 2 . Current relevant history physical psychiatric illness . 3 . Known suspected intolerance hypersensitivity investigational product , closelyrelated compound , state ingredient . 4 . Significant illness , judge investigator , within 2 week dose investigational product . 5 . Known history alcohol substance abuse within last year . 6 . Donation blood blood product ( eg , plasma platelet ) within 60 day prior dose investigational product . 7 . Within 30 day prior dose investigational product : Have use investigational product ( elimination halflife &lt; 6 day , otherwise 5 halflives ) . Have enrol clinical study ( include vaccine study ) , investigator 's opinion , may impact Shiresponsored study . Have substantial change eat habit , assess investigator . 8 . Confirmed systolic blood pressure &gt; 139mmHg &lt; 89mmHg , diastolic blood pressure &gt; 89mmHg &lt; 49mmHg . 9 . Twelvelead ECG demonstrate QTc &gt; 450 msec screening . If QTc exceed 450msec , ECG repeat 2 time average 3 QTc value use determine subject 's eligibility . 10 . A positive screen drug abuse Screening positive screen alcohol drug abuse Checkin ( Day 1 ) . 11 . Male subject consume 21 unit alcohol per week 3 unit alcohol per day . 12 . A positive human immunodeficiency virus antibody screen , hepatitis B surface antigen , hepatitis C virus antibody screen . 13 . Use tobacco form 14 . Routine consumption 2 unit caffeine per day 15 . Current use medication include overthecounter , herbal , homeopathic preparation 16 . An inability follow standardize diet meal schedule inability fast 17 . Have participate [ 14C ] study within last 6 month prior dose investigational product . 18 . Exposure clinically significant radiation within 12 month prior dose investigational product</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>ADME</keyword>
</DOC>